**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 47632

**Manuscript Type:** REVIEW

**Anti-inflammatory properties of antidiabetic agents**

Xourgia E *et al*. Anti-inflammatory properties of antidiabetic agents

Eleni Xourgia, Eleni-Margarita Tzouganatou, Athanasia Papazafiropoulou, Andreas Melidonis

**Eleni Xourgia, Eleni-Margarita Tzouganatou, Athanasia Papazafiropoulou, Andreas Melidonis,** 1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, Athens 18536, Greece

**ORCID number:** Eleni Xourgia (0000-0001-5766-3209); Eleni-Margarita Tzouganatou (0000-0002-3074-652X); Athanasia Papazafiropoulou (0000-0002-7596-4942); Andreas Melidonis (0000-0003-0505-5708).

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** No potential conflicts of interest. No financial support.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Athanasia Papazafiropoulou,** **MD, MSc, PhD, Attending Doctor, Research Scientist,** 1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, 1 Zanni and Afentouli Street, Athens 18536, Greece. pathan@ath.forthnet.gr

**Telephone:** +30-697-996483

**Received:** March 19, 2019

**Peer-review started:** March 19, 2019

**First decision:** April 13, 2019

**Revised:** April 20, 2019

**Accepted:** April 23, 2019

**Article in press:**

**Published online:**

**Abstract**

The reciprocal relationship between hyperglycemia and inflammation in the setting of diabetes mellitus has been the subject of extensive research. Insulin resistance, the hallmark of diabetic metabolic dysregulation, has been linked to the inflammatory cascade occurring mainly in adipose tissue. The main pathophysiologic processes facilitating the aforementioned interplay, is a phenotype switch of macrophages to the M1 class following gluco- and lipotoxicity and gut microbial remodeling. Given the correlation between inflammation and metabolic abnormalities, the elucidation of the exact mechanisms linking the two along with exploring the possible role of modulation of one in order to alter the other, could open up the possibility of novel therapeutic approaches for diabetes mellitus and its complications. Therefore, the aim of this review is to summarize the growing body of evidence concerning the molecular basis and results of pro-inflammatory processes in diabetic subjects along with the effect of current antidiabetic treatment options on tissue inflammation.

**Key words:** Inflammation; Adipose tissue; Anti-inflammatory; Type 2 diabetes mellitus; Antidiabetic drugs

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In this review, we aim to create a concise overview of the interplay between hyperglycemia and inflammation, while describing the immunomodulatory potential of each antidiabetic drug and its effects exerted in the inflammatory cascade in subjects with type 2 diabetes.

Xourgia E, Tzouganatou EM, Pazafiropoulou A, Melidonis A. Anti-inflammatory properties of antidiabetic agents. *World J Meta-Anal* 2019; In press

**INTRODUCTION**

Type 2 diabetes mellitus (T2DM) is currently considered a worldwide epidemic. It is regarded as one of the most important chronic conditions because of the high disease prevalence and its debilitating chronic complications, responsible for elevated indexes of morbidity and mortality. According to World Health Organization, the number of people affected by diabetes in 2014 has approximately quadrupled since 1980, worldwide. In detail, the age-standardized prevalence of diabetes in adults has nearly doubled since 1980, reaching 8.5%[1].

While the development of diabetes and its complications is a multifactorial process, the interplay between innate and acquired immunity in the pathogenesis of metabolic diseases has been attracting increasing research interest, mainly in the context of seeking novel treatment approaches and, ultimately, a causative therapy. Inflammation has been speculated to play an important role, central to the pathophysiologic dysregulation of the pancreatic islet in type 1 diabetics. Furthermore, growing evidence suggests that inflammation also affects the pathogenetic process of T2DM, modulating processes like obesity-related insulin resistance, impaired insulin secretion, and diabetes-related vascular dysfunction[2]. Furthermore, it is now understood that inflammation plays a major role in the pathogenesis of cardiovascular disease with ongoing research in the field of prevention of coronary artery disease by use of anti-inflammatory drugs[3-6]. Therefore, the purpose of this review is to discuss the potential anti-inflammatory effects of currently available antidiabetic medications in relation to the disruption of metabolic homeostasis.

**TYPE 2 DIABETES AND INFLAMMATION**

Adipocytes are the main site of interplay between inflammation and insulin resistance in T2DM. The immunomodulatory role of adipose tissue has now been well-described, as adipocytes not only produce various adipocytokines that can interfere with insulin production and sensitivity but interact in close communication with the immune cells surrounding them[7]. Adipose tissue macrophages affect tissue remodeling and metabolic balance through presenting with an M2 phenotype in lean fat[8]. The activity and expression patterns of M2 macrophages depend heavily on cytokine signaling cascades, namely those including interleukin (IL)-4 and IL-13. Macrophages shifted to the M2 phenotype produce arginase and IL-10[9]. In obesity, macrophages proliferate and shift to the M1 phenotype, activated by pro-inflammatory cytokines. M1 macrophages express CD11c and produce tumor necrosis factor-α (TNF-α), IL-6, and reactive oxygen species (ROS)[9]. The accumulation of M1 macrophages is incremental in the development of insulin resistance[7]. Adipose tissue inflammation can also be induced by localized decreased oxygen perfusion in tissues rapidly expanding with disproportional to the proliferation vascular adaptation[10].

In diabetes, hyperglycemia and elevated levels of free fatty acids (FFAs) may act as proinflammatory stimulants through the induction of glucose utilization and modulating the process of oxidative phosphorylation[11,12]. Such metabolic dysregulation has been shown to induce a proinflammatory shift in adipose, islet and vascular tissue-related anti-inflammatory cells[7-9]. Glucotoxicity and lipotoxicity fuel processes induce oxidative and endoplasmic reticulum stress, further initiating inflammation by activation of thioredoxin-interacting protein and the NLR family, pyrin domain containing 3 (NLRP3) inflammasome, which increase the release of active IL-1β[11-14]. IL-1β plays an important initiator role in the inflammatory cascade, recruiting macrophages and other cells of the immune response (“auto-stimulation”)[14]. The same interplay between metabolic dysregulation and inflammation occur between other tissue and cell types in the pancreas and circulatory system[13,14]. In T2DM, amyloid depositions in pancreatic islets induce inflammation through NLRP3 inflammasome formation and the production of IL-1β[15]. Increasing stress and inflammation, instigated in a positive-feedback manner, trigger cellular pro-apoptotic cascades and β-cell impairment, insulin resistance, and arterial atheromatosis.

Additionally, obesity is associated with alterations in the gut microbiome leading to functional changes of inherent gut homeostasis, with bacterial wall lipopolysaccharides (endotoxins) further promoting tissue inflammation[16]. Endotoxins, FFAs and cholesterol have a pro-inflammatory capacity through the activation of Toll-like receptor (TLR) pathways and, subsequently, nuclear factor-κB (NF-κB)-mediated cytokine and chemokine signaling including TNF-α, IL-1β, IL-8, and monocytes chemoattractant protein-1 (MCP-1) promoting immune cell attraction in several tissue types[17]. It has recently been reported that in obesity, gut microbiota aberrant growth patterns might affect the innate and acquired immune system responses, thereby promoting insulin resistance[18].

The interplay of metabolism and inflammation could justify the theory that metabolic dysfunction amelioration through lifestyle modification and pharmaceutical intervention could attenuate inflammation. Current antidiabetic treatments induce normoglycemia by acting on several different pathways. Many of these treatments also exert anti-inflammatory effects that might be mediated *via* their hypoglycemic and hypolipidemic capacities or by directly modulating the immune system. Below, we gather and discuss the current data on the anti-inflammatory properties of antidiabetic medications.

**ANTIDIABETIC TREATMENT AND INFLAMMATION**

***Metformin***

Metformin is considered a first-line treatment for T2DM in almost all guidelines and expert recommendations issued worldwide. The molecular mechanisms behind the pharmacologic activity of metformin appear to be rather complex and remain controversial. However, it is universally accepted that metformin phosphorylates and activates AMP-activated protein kinase (AMPK)[19]. In the liver, the AMPK cascade activates fatty acid oxidation with inhibition of cholesterol and triglyceride synthesis[19]. Peripheral effects include the activation of fatty acid oxidation and glucose uptake in skeletal muscle as well as a systemic increase in insulin sensitivity[19].

It has been reported that metformin increased nitric oxide (NO) synthesis via activation of AMPK[20] and decreased ROS production through inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and the respiratory mitochondrial chain[21]. Another study showed that metformin inhibited NFκB activation in the vessel wall and decreased serum C-reactive protein (CRP) level in high-fat-fed atherogenic rabbits[22]. Furthermore, Isoda *et al*[23] have reported that metformin inhibited NFκB activation through blockade of the phosphoinositide 3-kinase (PI3K)-Akt pathway in human vascular wall cells. Also, in lipopolysaccharide-activated macrophages, metformin inhibited production of the IL-1β precursor molecule and other pro-inflammatory cytokines, while it boosted induction of the anti-inflammatory cytokine, IL-10[24]. Another possible mechanism of the anti-inflammatory action of metformin is inhibition of advanced glycation end products (AGEs) formation. Metformin inhibits the formation of AGEs which promote inflammation and ROS (glycoxidation)[25].

Apart from the studies where the molecular effects of metformin were examined in vitro, there are also clinical studies. In the Diabetes Prevention Program (DPP) study, metformin slightly reduced the levels of CRP compared with placebo[26]. Similar results were provided by the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial, in which metformin and/or a thiazolidinedione (TZD) led to lower plasma insulin, lower plasminogen activator inhibitor type 1 (PAI-1) antigen, lower CRP and lower fibrinogen levels compared with a sulphonylurea (SU) or meglitinide in a population of diabetic patients with coronary artery disease[27]. Krysiak *et al*[28] have reported that metformin reduced monocyte release of TNF-α, IL-1β, IL-6, MCP-1 and IL-8, as well as plasma CRP level in patients with impaired fasting glucose. On the other hand, in the LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients with Type 2 Diabetes, metformin did not alter inflammatory biomarkers in patients with a short T2DM duration, in spite of glucose regulation[29]. In addition, it has been reported that metformin treatment did not change CRP or 8-iso-prostaglandin F2α(8-iso-PGF2α) level in subjects with normal glucose tolerance[30].

Overall, the various results are conflicting and even though metformin seems to have several anti-inflammatory pharmacologic properties *in vitro*, those are not always observed *in vivo*. Therefore, it remains uncertain whether the anti-inflammatory effect of metformin is due to its direct tissue-action or, induced indirectly, through the improvement of insulin sensitivity and hyperglycemia.

***Sulphonylureas***

Apart from the potent hypoglycemic effect of SUs, many studies have shown that they may have additional anti-inflammatory potential. Glyburide has been shown to inhibit the NLRP3 inflammasome and subsequent IL-1β activation in macrophages[31] while gliclazide, as compared with glibenclamide, decreased the serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin and high sensitive CRP (hsCRP), in a population of diabetic patients[32]. Mu-Huo *et al*[33] showed that in an animal model of sepsis, glibenclamide pretreatment exerted protective properties on the lung parenchyma by inhibiting both the inflammatory responses and oxidative stress. In addition, glibenclamide reduces pro-inflammatory cytokine production by neutrophils in patients with diabetes in response to bacterial infection[34]. Mavridis *et al*[35] reported that T2DM patients treated with SU had significantly lower cytokine levels than the insulin-treated.

By contrast, in various head-to-head clinical trials, no significant changes in CRP and other inflammatory markers were observed with SU therapy, whereas significant reductions were found with TZD, pioglitazone and the glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1 RA) exenatide[36-38]. Also, in a recent 52-wk head-to-head study between metformin, gliclazide, and pioglitazone on pro-inflammatory biomarkers, coagulation, and endothelial function, no improvements were seen in the circulating levels of inflammatory markers selected (IL-1, IL-6, and TNF-α) with SU therapy when compared to the other treatment types, while glycemic control was comparamble among all treatment groups[39].

It is notable that while SU appears to have some effect in the expression of various inflammatory cytokines, its anti-inflammatory effect is less potent when compared to metformin or pioglitazone.

***Alpha-glucosidase inhibitors***

Alpha-glucosidase (α-glucosidase) inhibitors are a unique class of antidiabetic medications which, by competitive and reversible inhibition of intestinal alpha-glucosidases, delay carbohydrate digestion and thereby extend the total time of glucose absorption[40]. Given the research data suggesting that postprandial glucose load results in a biomarker profile consistent with systemic low-grade inflammation and endothelial dysfunction, with increased levels of hsCRP, IL-6, TNF-α, sICAM-1, soluble vascular cell adhesion molecule 1 (sVCAM-1), E-selectin, and metalloproteinases (MMPs) 2 and 9 in patients with T2DM compared to healthy patients[41], α-glucosidase inhibitors are expected to have anti-inflammatory potential, justified by their mechanism of action.

Osonoi *et al*[42] suggested that miglitol depresses the production and release of inflammatory cytokines/cytokine-like factors in peripheral leukocytes by flattening glucose level fluctuation curves in Japanese patients with T2DM, incrementally more than other α-glucosidase inhibitors. Emoto *et al*[43] studied patients with T2DM and coronary artery disease on a 3-mo regimen of miglitol and demonstrated an improvement in both the insulin resistance index and CRP. Derosa *et al*[44] evaluated effects of acarbose in patients with T2DM and found it to be effective in reducing the post-oral-fat-load peaks of various parameters including inflammatory markers such as hsCRP, after 7 mo of therapy.

In a randomized double-blind, placebo-controlled crossover study, acarbose- induced normoglycemia did not affect adiponectin, insulin sensitivity, or pro-inflammatory circulating biomarkers (MCP-1, IL-6, and IL-1β)[45]. Similarly, a comparison of pioglitazone *vs* voglibose by Fujitaka *et al*[46] showed an improvement in serum adiponectin, hsCRP levels and insulin resistance assessment through the homeostatic model only in the pioglitazone group.

While, α-glucosidase inhibitors may have some indirect anti-inflammatory properties mainly *via* lowering the post prandial glucose levels, they do not seem to have further immunomodulatory potential.

***Thiazolidinedione***

Rosiglitazone and pioglitazone, also known as TZDs, are selective agonists of nuclear transcription factor peroxisome proliferator-activated receptor-γ (PPAR-γ).

There is plenty of scientific evidence that TZDs act not only as hypoglycemic medications but as anti-inflammatory agents as well. Specifically, PPAR-γ is mainly expressed in adipocytes and appears to attenuate pro-inflammatory biomarkers in visceral adipose tissue (VAT) deposits, steatotic liver, atherosclerotic plaques and plasma. Furthermore, in vitro results demonstrate that the anti-inflammatory activity of TZDs is partially resulting from their modulatory properties in glucocorticoid nuclear translocation activation, in a PPAR-γ-independent manner[47].

TZDs have been shown to decrease inflammatory markers in visceral adipose tissue, liver, atherosclerotic plaques, and circulating plasma[48]. Pioglitazone treatment decreased invasion of adipose tissue by proinflammatory macrophages and increased hepatic and peripheral insulin sensitivity in obese subjects[49]. Patients with insulin resistance had a decreased total adipose macrophage population, with a decrease in M1 macrophages and an increase in M2 macrophages with pioglitazone treatment[50]. Also, treatment with TZDs attenuated inflammation in nonalcoholic steatohepatitis and in atherosclerotic lesions[51,52].

The notion that PPAR-γ activation by TZDs can modulate monocyte and macrophage activity and have an impact on the inflammatory process is supported by *in vitro* research data. Further evidence of this is provided by studies *in vivo*, both in animal models and in humans. Haffner *et al*[53] in their study of approximately 300 T2DM patients on a 26-wk rosiglitazone treatment regimen, reported a reduction of at least 20% in plasma CRP levels and MMP-9 and approximately 12% in total white blood cell count. A reduction in MMP-9 was also observed by Marx *et al*[54] along with a concomitant decrease in plasma sCD40 levels (another emerging marker of inflammation and cardiovascular risk) in T2DM patients with established cardiovascular disease, following rosiglitazone treatment.

In addition, a recent meta-analysis of 27 randomized controlled trials, found that circulating levels of hsCRP, monocyte chemoattractant protein-1, von Willebrand factor, fibrinogen, and E-selectin were significantly decreased after TZD therapy. However, IL-6, MMP-9, sCD40 ligand, PAI-1 and ICAM-1 were not significantly affected[55]. In the PERISCOPE trial, treatment of diabetic patients with known coronary artery disease with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis and a decrease in hsCRP levels, compared with glimepiride[56].

Nonetheless, one could argue that all the aforementioned anti-inflammatory actions of TZDs can be attributed to their effect on glucose lowering. Satoh *et al*[57], following pioglitazone treatment in T2DM, observed a decrease in CRP levels of the same magnitude both in patients who responded to therapy (defined as an improvement in glucose control) and in non-responders. Also, Nitta *et al*[58] showed that, compared with glimepiride, pioglitazone reduced coronary arterial inflammation in patients with T2DM or impaired glucose tolerance, even though both agents decreased glucose-control related parameters such as HbA1c and fasting plasma glucose.

TZDs appear to be potent modulators of the inflammatory cascade, independently of their glucose lowering effect. Currently, various studies examine their potential use as immunomodulators outside the setting of diabetes, in normoglycemic subjects with rheumatic and other auto-immune diseases[59,60].

***SGLT-2 inhibitors***

Sodium–glucose cotransporter (SGLT) 2 inhibitors improve glycemia by inhibiting reabsorption of glucose in the proximal tubule of the kidney, inducing glucosuria and lowering plasma glucose levels, without inducing hypoglycemia.

In T2DM mice, the SGLT-2 inhibitor ipragliflozin was shown to improve hyperglycemia, insulin secretion, hyperlipidemia, and liver levels of oxidative stress biomarkers and reduce markers of inflammation including IL-6, TNF-α, MCP-1, and CRP levels[61]. In another study, short-term luseogliflozin treatment normalized the expression of inflammation-related genes such as F4/80, TNFα, IL-1β, IL-6, ICAM-1, platelet endothelial cell adhesion molecule-1 (PECAM-1), MMP2 and MMP9 in apolipoprotein-E deficient knockout (ApoE KO) mice, while markedly attenuating the progression of atherosclerosis[62]. Another study in mice treated with empagliflozin provided similar results[63]. Furthermore, empagliflozin reduced M1-polarized macrophage accumulation while inducing the anti-inflammatory M2 phenotype of macrophages within adipose tissue and liver, lowering plasma TNFα levels and attenuating obesity-related chronic inflammation in diet-induced obese mice[64]. Also, empagliflozin, alone or in combination with linagliptin, attenuated (nonalcoholic steatohepatitis) NASH development in diabetic mice, through reducing hepatic expression of inflammatory genes (TNF-α, IL-6, and MCP-1)[65]. Dapagliflozin also reduced mRNA levels of various cytokines and attenuated the development of diabetic cardiomyopathy in diabetic mice[66].

Moreover, there is evidence that the important renoprotective effect of SGLT-2 inhibitors is partly due to their anti-inflammatory properties. Vallon *et al*[67]showed that administration of empagliflozin in diabetic mice not only attenuated glomerular hyperfiltration, albuminuria, but also inhibited diabetes-induced renal expression of inflammation markers, such as NF-κB and IL-6. Hatanaka *et al*[68] reported that the administration of dapagliflozin to Akita mice induced an incremental renal macrophage tissue accumulation and attenuated interstitial fibrosis when compared with insulin, despite glycemic control being equally efficient in the two groups, indicating that dapagliflozin exerts renoprotective effects beyond glucose reduction. In addition, studies using cultured proximal tubular cells support the notion that a decrease in the expression and circulation of pro-inflammatory molecules, such as transforming growth factor-β, MCP-1, osteopontin, and ICAM-1, oxidative stress, NADPH oxidase 4 (Nox4) expression and ROS production underlie the major actions of dapagliflozin[69].

In a small study with 32 male diabetic patients empagliflozin and canagliflozin lowered interferon-λ, TNF-α, IL-6[70]. Sato *et al*[71] studied the effect of dapagliflozin on epicardial adipose tissue and observed that treatment with dapagliflozin resulted in a slight reduction of serum PAI and a greater reduction of serum TNF-a in T2DM patients with coronary artery disease. Okamoto *et al*[72] studied the effects of dapagliflozin on several biomarkers using a population of 27 obese T2DM patients and showed that dapagliflozin treatment led to a significant increase in serum adiponectin and a mild decrease in CRP. A small decrease in CRP with dapagliflozin treatment was also observed in another study[73]. In a post-hoc exploratory analysis of the CANTATA-SU study, changes from baseline in serum leptin, adiponectin, IL-26, TNF-a, CRP, PAI-1, VCAM-1 and MCP-1 were measured in T2DM patients taking metformin, but also receiving either canagliflozin or glimepiride. Canagliflozin shifted the balance of appetite-related hormones, significantly decreasing median serum leptin and increasing median serum adiponectin when compared to glimepiride. Median serum IL-6 was accordingly decreased as well accompanied by a trend towards a slight reduction in hsCRP which, however, contrasted with a modest increase in median serum TNF-a in the canagliflozin group over glimepiride. Despite changes in serum leptin being associated with changes in body weight, there were no notable correlations between changes in adiponectin, IL-6, TNF-a and CRP levels and alterations in body weight and HbA1c[74].

The majority of studies that have been discussed above used animal models. Evidence from clinical trials in human subjects is limited and as a result it is not safe to reach a conclusion regarding the anti-inflammatory effect of this particular category.

***DPP-4 inhibitors***

Dipeptidyl peptidase (DPP)-4 inhibitors reduce DPP-4 activity in peripheral plasma, preventing the inactivation of the incretin hormone GLP)-1[75]. The ubiquitous tissue localization of DPP-4 (monocytes, natural killer cells, macrophages, epithelial and endothelial cells, lung, spleen, pancreas, kidney, liver and intestinal cells) could play a role in explaining the immunomodulatory role of this enzyme. DPP-4 hormone production in macrophages, especially in visceral adipose tissue depots, binds to adenosine deaminase, facilitating, *via* nonenzymatic function, T-cell proliferation and activation. Also, CD26, which can partially act as an *in vivo* DPP-4 mimic, serves as a signaling molecule in T-cell activation and immunoregulation [76].

The DPP-4 inhibitor alogliptin can attenuate TLR-4 mediated extracellular signal regulated kinase (ERK) activation and ERK-dependent expression of MMPs in histiocytes, and inhibit TLR4-mediated IL-6 and IL-1-beta production[77]. In human macrophages cultured *in vitro*, the DPP-4 inhibitor sitagliptin significantly increased GLP-1 induced the levels of cyclic adenosine monophosphate (cAMP) in the cytosol, resulting in hindering of NF-κB p65 nuclear translocation and suppression of pro-inflammatory mediator production in response tolipopolysaccharide (LPS)[78]. Treatment with linagliptin notably suppressed the activation of the fibrotic process in an experimental model of autoimmune myocarditis mice and was associated with reduced inflammatory cytokine (IL-2, TNF-α, IL-1β, and IL-6) gene expression[79]. Another study indicated that sitagliptin treatment of obese insulin-resistant mice was associated with an improved metabolic phenotype and concurrent reduction of inflammation in pancreatic islets and adipose tissue[80]. In diabetic rats, sitagliptin decreased circulating levels of CRP, MCP-1, TNF-α, IL-6, PAI-1, and suppressed vascular smooth muscle cells proliferation[81].

Surface expression of CD26 on CD4+ and CD8+ T-cells was found to be higher in T2DM patients when compared to healthy controls[82]. In a recent study concerning the production of inflammatory mediators, treatment with sitagliptin for 12 wk reduced mRNA expression of CD26, TNF-α, TLR2, TLR4, proinflammatory kinases c-Jun N-terminal kinase-1 and inhibitory κB kinase, and inhibitor of chemokine receptor CCR-2 in mononuclear cells, as well as of plasma CRP, IL-6, and FFAs[83]. Similarly, another study showed that sitagliptin reduced the expression of inflammatory cytokines and improved the unfavorable M1/M2 phenotypes of peripheral blood monocytes in Japanese diabetic patients[84]. Treatment with sitagliptin or vildagliptin lowered plasma IL-6, IL-18, TNF-alpha and nitrotyrosine levels compared with baseline in T2DM patients[85]. Furthermore, in a study of subjects with coronary artery disease and uncontrolled T2DM, sitagliptin significantly improved endothelial function and inflammatory state beyond its hypoglycemic action[86]. In hemodialysis patients with T2DM, linagliptin decreased levels of prostaglandin E2, IL-6, hsCRP, glycated albumin, and blood glucose which was associated with an increase in active GLP-1[87]. However, on a model of sitagliptin or metformin as add-on therapy to a pioglitazone regimen in patients with poorly controlled T2DM demonstrated that only metformin led to a decrease of body weight and to a faster and superior improvement of insulin resistance and inflammatory parameters, such as adiponectin and TNF-a[88].

In summary, research suggests that all currently available DPP-4 inhibitors have multiple immunomodulatory effects, in a way that is independent of their glucose lowering effect.

***GLP-1 receptor agonists***

GLP-1 receptor agonists have been shown to activate GLP-1 receptor to increase the intracellular concentration of cAMP in acinar cells of the pancreas, resulting in an increased insulin secretion and decreased glucagon secretion.

In patients with T2DM, treatment with GLP-1 analogs appears to modulate the pro-inflammatory activity of the innate immune system, leading to reduced pro-inflammatory activation of macrophages and consequently the expression and secretion of proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6 and increased adiponectin. This effect is not dependent on the glycemic or body weight effects of GLP-1[89]. With regard to the effects of GLP-1 analogs on CRP, a small placebo-controlled study demonstrated a significant reduction in CRP levels with exenatide[90]. Also, in a 12-mo comparative study, exenatide demonstrated a significant decrease in hsCRP compared with SU[37].

Treatment of cultured human islets with exendin-4, a GLP-1 RA, suppressed the expression of inflammatory genes such as NFκB1(p105), NFκB2(p100), RelA (also termed p65), TNF receptor superfamily member 1A, and receptor-interacting serine/threonine kinase 2[91]. In addition, administration of a recombinant adenovirus producing GLP-1 to ob/ob mice reduced the macrophage population and production of TNF-α, MCP-1, and IL-6 in adipose tissue via inhibition of NF-κΒ activation and phosphorylation of ERK1/2 and c-Jun N-terminal kinases[92]. Also, Arakawa *et al*[93]observed that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, in C57BL/6 or apolipoprotein E-deficient mice apoE(-/-). In another study, exenatide significantly increased the level of IL-10 and decreased both TNF-α and IL-1β in LPS-treated monocytes/macrophages, via activation of protein kinase A[94].

Exendin-4 also prevented macrophage infiltration, and decreased protein levels of ICAM-1 and type IV collagen, as well as decreasing oxidative stress and NF-κB activation in kidney tissue, in a rat model of type 1 diabetes[95]. Furthermore, Kim *et al*[96], showed that exendin-4 had an anti-inflammatory, neuroprotective effect in mice after a stroke, through inhibition of COX-2 through modulating JNK signaling-mediated stimulation of islet brain 1. Moreover, exendin-4 treatment reduced hepatic expression of the inflammatory markers TNF-α, IL-1β, and IL-6 and macrophage markers, cluster of differentiation 68 (CD68), and F4/80 in the liver of mice fed a western-type diet[97,98].

In addition, exenatide plus metformin resulted in a significant reduction in CRP and TNF-α compared with baseline[99]. In another study, treatment of diabetic patients with exenatide for 1 year significantly reduced increased total adiponectin by 12% and reduced hsCRP by 61% and these changes were statistically independent of the change in total body fat mass and body weight[100]. Moreover, Daousi *et al*[101] showed that GLP-1 continuous infusion in patients with T2DM was associated with a significant reduction in circulating IL-6 at 120 and 180 min post-administration. In a retrospective analysis of 110 obese patients with T2DM treated with liraglutide, the mean concentration of CRP declined after treatment with liraglutide for a mean duration of 7.5 mo[102].

Overall, the results of a number of studies all agree that GLP-1 RAs present many anti-inflammatory properties via multiple molecular pathways. It is also important to underscore that these immunomodulatory effects seem to be independent of their metabolic effects in weight and glucose lowering.

***Insulin***

Insulin induces an attenuation of inflammatory processes through several mechanisms, including increased endothelial nitric oxide release and decreased expression of proinflammatory cytokines and immune mediators, such as NF-κB, ICAM-1, and MCP-1, as well as several TLRs[103].

In a randomized parallel-group study in patients with T2DM, serum concentrations of hsCRP and IL-6 were markedly reduced in insulin-treated patients compared with metformin, despite the achievement of similar glycemic control[104]. This may suggest that insulin reduces inflammation, irrespectively of its effects on glycemia. In another study, treatment of insulin in patients with poorly controlled T2DM reduced serum hsCRP levels, without affecting plasma fibrinogen or serum MCP-1 levels[105]. In contrast, in the LANCET trial, treatment with insulin compared with a placebo or metformin did not reduce inflammatory biomarker levels despite improving glucose control[29]. Also, Jansen *et al*[106] observed that patients characterized by a pronounced insulin-associated weight gain had an influx of macrophages into the adipose tissue and higher protein levels of MCP-1, TNF-α and IL-1β after 6 mo of insulin therapy compared with those who had not gained weight.

Overall, the results of the various studies concerning insulin are rather conflicting. It is unclear both whether insulin has notable anti-inflammatory properties and whether or not they correlate with its hypoglycemic effect. The lack of large, randomized, double-blind, controlled trials on the subject, or head-to-head studies with other antidiabetic agents, is a major limitation in drawing safe conclusions.

**CONCLUSION**

The inflammatory process and its causal relationship with the pathophysiology of diabetes mellitus and its complications remains a rather complex matter due to the numerous intertwining pathways involved in various tissue types, along with the interpersonal multifactorial variation of the inflammatory response. While the antidiabetic agents and their indications in the treatment algorithm are mainly evaluated based on their glucose lowering attributes, their immunomodulatory potential, most importantly on M1 macrophages could carry great therapeutic benefit, especially in highly insulin resistant patients. Another point of great interest when discussing the aforementioned attributes of these agents is whether the attenuation of the inflammatory cascade activation is secondary to normoglycemia achievement or independent to glycemic regulation, a differentiation that significantly alters the appropriate setting in which they could be successfully introduced to a particular anti-inflammatory-oriented treatment regimen. Moreover, most of the research data on the subject derives from studies on animal subjects, with large, randomized, double-blind studies lacking at the moment, a fact that does not allow for safe conclusions to be drawn as far as clinical correlation of molecular changes is concerned. In conclusion, there is need for further research quantifying the immunomodulatory capacity of antidiabetic agents, elucidating the mechanisms by which those effects are induced and exploring whether those theoretical alterations in circulatory and tissue cytokine and cell-phenotype patterns can be translated into clinical benefit for diabetes and its complications.

**REFERENCES**

1 **Wild S**, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004; **27**: 1047-1053 [PMID: 15111519 DOI: 10.2337/diacare.27.5.1047]

2 **Pollack RM**, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. *Diabetes Care* 2016; **39 Suppl 2**: S244-S252 [PMID: 27440839 DOI: 10.2337/dcS15-3015]

3 **Hansson GK**. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; **352**: 1685-1695 [PMID: 15843671 DOI: 10.1056/NEJMra043430]

4 **Ridker PM**, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* 2000; **342**: 836-843 [PMID: 10733371 DOI: 10.1056/NEJM200003233421202]

5 **Bohula EA**, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. *Circulation* 2015; **132**: 1224-1233 [PMID: 26330412 DOI: 10.1161/CIRCULATIONAHA.115.018381]

6 **Ridker PM**, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM, Glynn RJ. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur Heart J* 2018; **39**: 3499-3507 [PMID: 30165610 DOI: 10.1093/eurheartj/ehy310]

7 **Kohlgruber A**, Lynch L. Adipose tissue inflammation in the pathogenesis of type 2 diabetes. *Curr Diab Rep* 2015; **15**: 92 [PMID: 26374569 DOI: 10.1007/s11892-015-0670-x]

8 **Sun K**, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. *J Clin Invest* 2011; **121**: 2094-2101 [PMID: 21633177 DOI: 10.1172/JCI45887]

9 **Lumeng CN**, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J Clin Invest* 2007; **117**: 175-184 [PMID: 17200717 DOI: 10.1172/JCI29881]

10 **Ye J**. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. *Int J Obes (Lond)* 2009; **33**: 54-66 [PMID: 19050672 DOI: 10.1038/ijo.2008.229]

11 **Maedler K**, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. *J Clin Invest* 2002; **110**: 851-860 [PMID: 12235117 DOI: 10.1172/JCI15318]

12 **Zhou R**, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. *Nat Immunol* 2010; **11**: 136-140 [PMID: 20023662 DOI: 10.1038/ni.1831]

13 **Vandanmagsar B**, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. *Nat Med* 2011; **17**: 179-188 [PMID: 21217695 DOI: 10.1038/nm.2279]

14 **Dinarello CA**. Immunological and inflammatory functions of the interleukin-1 family. *Annu Rev Immunol* 2009; **27**: 519-550 [PMID: 19302047 DOI: 10.1146/annurev.immunol.021908.132612]

15 **Masters SL**, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N, Mielke LA, Harris J, Coll RC, Mills KH, Mok KH, Newsholme P, Nuñez G, Yodoi J, Kahn SE, Lavelle EC, O'Neill LA. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. *Nat Immunol* 2010; **11**: 897-904 [PMID: 20835230 DOI: 10.1038/ni.1935]

16 **Ley RE**, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A* 2005; **102**: 11070-11075 [PMID: 16033867 DOI: 10.1073/pnas.0504978102]

17 **Nguyen MT**, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, Liu-Bryan R, Glass CK, Neels JG, Olefsky JM. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. *J Biol Chem* 2007; **282**: 35279-35292 [PMID: 17916553 DOI: 10.1074/jbc.M706762200]

18 **Sell H**, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. *Nat Rev Endocrinol* 2012; **8**: 709-716 [PMID: 22847239 DOI: 10.1038/nrendo.2012.114]

19 **Gong L**, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenet Genomics* 2012; **22**: 820-827 [PMID: 22722338 DOI: 10.1097/FPC.0b013e3283559b22]

20 **Davis BJ**, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. *Diabetes* 2006; **55**: 496-505 [PMID: 16443786 DOI: 10.2337/diabetes.55.02.06.db05-1064]

21 **Ouslimani N**, Peynet J, Bonnefont-Rousselot D, Thérond P, Legrand A, Beaudeux JL. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. *Metabolism* 2005; **54**: 829-834 [PMID: 15931622 DOI: 10.1016/j.metabol.2005.01.029]

22 **Li SN**, Wang X, Zeng QT, Feng YB, Cheng X, Mao XB, Wang TH, Deng HP. Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. *Heart Vessels* 2009; **24**: 446-453 [PMID: 20108078 DOI: 10.1007/s00380-008-1137-7]

23 **Isoda K**, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schönbeck U, Libby P. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. *Arterioscler Thromb Vasc Biol* 2006; **26**: 611-617 [PMID: 16385087 DOI: 10.1161/01.ATV.0000201938.78044.75]

24 **Kelly B**, Tannahill GM, Murphy MP, O'Neill LA. Metformin Inhibits the Production of Reactive Oxygen Species from NADH:Ubiquinone Oxidoreductase to Limit Induction of Interleukin-1β (IL-1β) and Boosts Interleukin-10 (IL-10) in Lipopolysaccharide (LPS)-activated Macrophages. *J Biol Chem* 2015; **290**: 20348-20359 [PMID: 26152715 DOI: 10.1074/jbc.M115.662114]

25 **Ruggiero-Lopez D**, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. *Biochem Pharmacol* 1999; **58**: 1765-1773 [PMID: 10571251 DOI: 10.1016/S0006-2952(99)00263-4]

26 **Haffner S**, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E; Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. *Diabetes* 2005; **54**: 1566-1572 [PMID: 15855347 DOI: 10.2337/diabetes.54.5.1566]

27 **Sobel BE**, Hardison RM, Genuth S, Brooks MM, McBane RD 3rd, Schneider DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL; BARI 2D Investigators. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Circulation* 2011; **124**: 695-703 [PMID: 21768545 DOI: 10.1161/CIRCULATIONAHA.110.014860]

28 **Krysiak R**, Okopien B. The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose. *Metabolism* 2013; **62**: 39-43 [PMID: 22841520 DOI: 10.1016/j.metabol.2012.06.009]

29 **Pradhan AD**, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. *JAMA* 2009; **302**: 1186-1194 [PMID: 19755697 DOI: 10.1001/jama.2009.1347]

30 **Lima LM**, Wiernsperger N, Kraemer-Aguiar LG, Bouskela E. Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen. *Clinics (Sao Paulo)* 2009; **64**: 415-420 [PMID: 19488607 DOI: 10.1590/S1807-59322009000500008]

31 **Lamkanfi M**, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. *J Cell Biol* 2009; **187**: 61-70 [PMID: 19805629 DOI: 10.1083/jcb.200903124]

32 **Räkel A**, Renier G, Roussin A, Buithieu J, Mamputu JC, Serri O. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. *Diabetes Obes Metab* 2007; **9**: 127-129 [PMID: 17199728 DOI: 10.1111/j.1463-1326.2006.00571.x]

33 **Mu-Huo J,** Jiao-Jiao Y, Lin-Sha J, Si-Hai Zhu, Jian-Jun Yang. Glibenclamide pretreatment attenuates acute lung injury by inhibiting the inflammatory responses and oxidative stress in a polymicrobial sepsis animal model. *J Anesth Perioper Med* 2014; **1**: 36-43. [DOI: 10.24015/JAPM.2014.0006]

34 **Kewcharoenwong C**, Rinchai D, Utispan K, Suwannasaen D, Bancroft GJ, Ato M, Lertmemongkolchai G. Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. *Sci Rep* 2013; **3**: 3363 [PMID: 24285369 DOI: 10.1038/srep03363]

35 **Mavridis G**, Souliou E, Diza E, Symeonidis G, Pastore F, Vassiliou AM, Karamitsos D. Inflammatory cytokines in insulin-treated patients with type 2 diabetes. *Nutr Metab Cardiovasc Dis* 2008; **18**: 471-476 [PMID: 17976964 DOI: 10.1016/j.numecd.2007.02.013]

36 **Derosa G**, Cicero AF, Fogari E, D'Angelo A, Bianchi L, Maffioli P. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. *Horm Metab Res* 2011; **43**: 505-512 [PMID: 21590648 DOI: 10.1055/s-0031-1275704]

37 **Derosa G**, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF. Exenatide versus glibenclamide in patients with diabetes. *Diabetes Technol Ther* 2010; **12**: 233-240 [PMID: 20151774 DOI: 10.1089/dia.2009.0141]

38 **Schöndorf T**, Musholt PB, Hohberg C, Forst T, Lehmann U, Fuchs W, Löbig M, Müller J, Pfützner A. The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. *J Diabetes Sci Technol* 2011; **5**: 426-432 [PMID: 21527115 DOI: 10.1177/193229681100500233]

39 **Erem C**, Ozbas HM, Nuhoglu I, Deger O, Civan N, Ersoz HO. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. *Exp Clin Endocrinol Diabetes* 2014; **122**: 295-302 [PMID: 24710641 DOI: 10.1055/s-0034-1370989]

40 **Bischoff H**. The mechanism of alpha-glucosidase inhibition in the management of diabetes. *Clin Invest Med* 1995; **18**: 303-311 [PMID: 8549017]

41 **Derosa G**, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF. Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. *Microvasc Res* 2010; **79**: 144-149 [PMID: 20079360 DOI: 10.1016/j.mvr.2010.01.002]

42 **Osonoi T**, Saito M, Mochizuki K, Fukaya N, Muramatsu T, Inoue S, Fuchigami M, Goda T. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus. *Metabolism* 2010; **59**: 1816-1822 [PMID: 20667563 DOI: 10.1016/j.metabol.2010.06.006]

43 **Emoto T**, Sawada T, Hashimoto M, Kageyama H, Terashita D, Mizoguchi T, Mizuguchi T, Motodi Y, Iwasaki M, Taira K, Okamoto H, Matsuo Y, Kim SK, Takarada A, Yokoyama M. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. *Am J Cardiol* 2012; **109**: 42-46 [PMID: 21944671 DOI: 10.1016/j.amjcard.2011.08.005]

44 **Derosa G**, Maffioli P, Ferrari I, Fogari E, D'Angelo A, Palumbo I, Randazzo S, Bianchi L, Cicero AF. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. *Eur J Pharmacol* 2011; **651**: 240-250 [PMID: 21118681 DOI: 10.1016/j.ejphar.2010.11.015]

45 **Shimazu T**, Inami N, Satoh D, Kajiura T, Yamada K, Iwasaka T, Nomura S. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients. *J Thromb Thrombolysis* 2009; **28**: 429-435 [PMID: 19137265 DOI: 10.1007/s11239-008-0301-3]

46 **Fujitaka K**, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, Nishikawa M, Iwasaka T. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome. *Endocr J* 2011; **58**: 425-432 [PMID: 21498915 DOI: 10.1507/endocrj.K10E-327]

47 **Ialenti A**, Grassia G, Di Meglio P, Maffia P, Di Rosa M, Ianaro A. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. *Mol Pharmacol* 2005; **67**: 1620-1628 [PMID: 15684043 DOI: 10.1124/mol.104.004895]

48 **Ceriello A**. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. *Diabetes Metab Res Rev* 2008; **24**: 14-26 [PMID: 17990280 DOI: 10.1002/dmrr.790]

49 **Esterson YB**, Zhang K, Koppaka S, Kehlenbrink S, Kishore P, Raghavan P, Maginley SR, Carey M, Hawkins M. Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients. *J Investig Med* 2013; **61**: 1152-1160 [PMID: 24141239 DOI: 10.2310/JIM.0000000000000017]

50 **Szanto A**, Nagy L. The many faces of PPARgamma: anti-inflammatory by any means? *Immunobiology* 2008; **213**: 789-803 [PMID: 18926294 DOI: 10.1016/j.imbio.2008.07.015]

51 **Boettcher E**, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2012; **35**: 66-75 [PMID: 22050199 DOI: 10.1111/j.1365-2036.2011.04912.x]

52 **Reiss AB**, Vagell ME. PPARgamma activity in the vessel wall: anti-atherogenic properties. *Curr Med Chem* 2006; **13**: 3227-3238 [PMID: 17168709 DOI: 10.2174/092986706778742909]

53 **Haffner SM**, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. *Circulation* 2002; **106**: 679-684 [PMID: 12163427 DOI: 10.1161/01.CIR.0000025403.20953.23]

54 **Marx N**, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. *Circulation* 2003; **107**: 1954-1957 [PMID: 12695287 DOI: 10.1161/01.CIR.0000069272.06194.91]

55 **Chen R**, Yan J, Liu P, Wang Z. Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: a meta-analysis of randomized controlled trials. *PLoS One* 2015; **10**: e0123703 [PMID: 25897968 DOI: 10.1371/journal.pone.0123703]

56 **Nissen SE**, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *JAMA* 2008; **299**: 1561-1573 [PMID: 18378631 DOI: 10.1001/jama.299.13.1561]

57 **Satoh N**, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. *Diabetes Care* 2003; **26**: 2493-2499 [PMID: 12941708 DOI: 10.2337/diacare.26.9.2493]

58 **Nitta Y**, Tahara N, Tahara A, Honda A, Kodama N, Mizoguchi M, Kaida H, Ishibashi M, Hayabuchi N, Ikeda H, Yamagishi S, Imaizumi T. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging. *JACC Cardiovasc Imaging* 2013; **6**: 1172-1182 [PMID: 24229770 DOI: 10.1016/j.jcmg.2013.09.004]

59 **Celinski K**, Dworzanski T, Fornal R, Korolczuk A, Madro A, Brzozowski T, Slomka M. Comparison of anti-inflammatory properties of peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis. *J Physiol Pharmacol* 2013; **64**: 587-595 [PMID: 24304573]

60 **Shahin D**, Toraby EE, Abdel-Malek H, Boshra V, Elsamanoudy AZ, Shaheen D. Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study). *Clin Med Insights Arthritis Musculoskelet Disord* 2011; **4**: 1-10 [PMID: 21339857 DOI: 10.4137/CMAMD.S5951]

61 **Tahara A**, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. *Eur J Pharmacol* 2013; **715**: 246-255 [PMID: 23707905 DOI: 10.1016/j.ejphar.2013.05.014]

62 **Nakatsu Y**, Kokubo H, Bumdelger B, Yoshizumi M, Yamamotoya T, Matsunaga Y, Ueda K, Inoue Y, Inoue MK, Fujishiro M, Kushiyama A, Ono H, Sakoda H, Asano T. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice. *Int J Mol Sci* 2017; **18** [PMID: 28777298 DOI: 10.3390/ijms18081704]

63 **Han JH**, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, Choi SH, Jang HC, Lee HS, Park KS, Kim YB, Lim S. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE <sup>-/-</sup> mice fed a western diet. *Diabetologia* 2017; **60**: 364-376 [PMID: 27866224 DOI: 10.1007/s00125-016-4158-2]

64 **Xu L**, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, Mayoux E, Kaneko S, Ota T. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. *EBioMedicine* 2017; **20**: 137-149 [PMID: 28579299 DOI: 10.1016/j.ebiom.2017.05.028]

65 **Jojima T**, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. *Diabetol Metab Syndr* 2016; **8**: 45 [PMID: 27462372 DOI: 10.1186/s13098-016-0169-x]

66 **Ye Y**, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. *Cardiovasc Drugs Ther* 2017; **31**: 119-132 [PMID: 28447181 DOI: 10.1007/s10557-017-6725-2]

67 **Vallon V**, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. *Am J Physiol Renal Physiol* 2014; **306**: F194-F204 [PMID: 24226524 DOI: 10.1152/ajprenal.00520.2013]

68 **Hatanaka T**, Ogawa D, Tachibana H, Eguchi J, Inoue T, Yamada H, Takei K, Makino H, Wada J. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. *Pharmacol Res Perspect* 2016; **4**: e00239 [PMID: 28116093 DOI: 10.1002/prp2.239]

69 **Terami N**, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, Eguchi J, Horiguchi CS, Nishii N, Yamada H, Takei K, Makino H. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. *PLoS One* 2014; **9**: e100777 [PMID: 24960177 DOI: 10.1371/journal.pone.0100777]

70 **Tan SA,** Tan L. Empagliflozin and canagliflozin attenuate inflammatory cytokines interferon-λ, tumor necrosis factor-α, intrleukin-6: possible mechanism of decreasing cardiovascular risk in diabetes mellitus. *J Am Coll Cardiol* 2018; **71 (11 Supplement)**: A1830 [DOI: 10.1016/S0735-1097(18)32371-4]

71 **Sato T**, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M. The effect of dapagliflozin treatment on epicardial adipose tissue volume. *Cardiovasc Diabetol* 2018; **17**: 6 [PMID: 29301516 DOI: 10.1186/s12933-017-0658-8]

72 **Okamoto A**, Yokokawa H, Sanada H, Naito T. Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients. *Drugs R D* 2016; **16**: 255-261 [PMID: 27333994 DOI: 10.1007/s40268-016-0137-9]

73 **Ferrannini E**, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care* 2010; **33**: 2217-2224 [PMID: 20566676 DOI: 10.2337/dc10-0612]

74 **Garvey WT**, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, Ren J, Davies MJ. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. *Metabolism* 2018; **85**: 32-37 [PMID: 29452178 DOI: 10.1016/j.metabol.2018.02.002]

75 **Thornberry NA**, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). *Best Pract Res Clin Endocrinol Metab* 2009; **23**: 479-486 [PMID: 19748065 DOI: 10.1016/j.beem.2009.03.004]

76 **Yang L**, Yuan J, Zhou Z. Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus. *Can J Diabetes* 2014; **38**: 473-479 [PMID: 25034244 DOI: 10.1016/j.jcjd.2014.01.008]

77 **Ta NN**, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. *J Cardiovasc Pharmacol* 2011; **58**: 157-166 [PMID: 21558879 DOI: 10.1097/FJC.0b013e31821e5626]

78 **Matsubara J**, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. *J Am Coll Cardiol* 2012; **59**: 265-276 [PMID: 22240132 DOI: 10.1016/j.jacc.2011.07.053]

79 **Hirakawa H**, Zempo H, Ogawa M, Watanabe R, Suzuki J, Akazawa H, Komuro I, Isobe M. A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. *PLoS One* 2015; **10**: e0119360 [PMID: 25768281 DOI: 10.1371/journal.pone.0119360]

80 **Dobrian AD**, Ma Q, Lindsay JW, Leone KA, Ma K, Coben J, Galkina EV, Nadler JL. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. *Am J Physiol Endocrinol Metab* 2011; **300**: E410-E421 [PMID: 21081706 DOI: 10.1152/ajpendo.00463.2010]

81 **Lim S**, Choi SH, Shin H, Cho BJ, Park HS, Ahn BY, Kang SM, Yoon JW, Jang HC, Kim YB, Park KS. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. *PLoS One* 2012; **7**: e35007 [PMID: 22493727 DOI: 10.1371/journal.pone.0035007]

82 **Lee SA**, Kim YR, Yang EJ, Kwon EJ, Kim SH, Kang SH, Park DB, Oh BC, Kim J, Heo ST, Koh G, Lee DH. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab* 2013; **98**: 2553-2561 [PMID: 23539735 DOI: 10.1210/jc.2012-4288]

83 **Makdissi A**, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, Dhindsa S, Dandona P. Sitagliptin exerts an antinflammatory action. *J Clin Endocrinol Metab* 2012; **97**: 3333-3341 [PMID: 22745245 DOI: 10.1210/jc.2012-1544]

84 **Satoh-Asahara N**, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K, Shimatsu A. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. *Metabolism* 2013; **62**: 347-351 [PMID: 23062489 DOI: 10.1016/j.metabol.2012.09.004]

85 **Rizzo MR**, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. *Diabetes Care* 2012; **35**: 2076-2082 [PMID: 22688551 DOI: 10.2337/dc12-0199]

86 **Matsubara J,** Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. *Circ J* 2013; **77**: 1337–1344 [DOI: 10.1253/circj.CJ-12-1168]

87 **Nakamura Y**, Tsuji M, Hasegawa H, Kimura K, Fujita K, Inoue M, Shimizu T, Gotoh H, Goto Y, Inagaki M, Oguchi K. Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes. *Hemodial Int* 2014; **18**: 433-442 [PMID: 24405885 DOI: 10.1111/hdi.12127]

88 **Derosa G**, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. *Metabolism* 2010; **59**: 887-895 [PMID: 20015525 DOI: 10.1016/j.metabol.2009.10.007]

89 **Hogan AE**, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O'Connell J, O'Shea D. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. *Diabetologia* 2014; **57**: 781-784 [PMID: 24362727 DOI: 10.1007/s00125-013-3145-0]

90 **Wu JD**, Xu XH, Zhu J, Ding B, Du TX, Gao G, Mao XM, Ye L, Lee KO, Ma JH. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. *Diabetes Technol Ther* 2011; **13**: 143-148 [PMID: 21284481 DOI: 10.1089/dia.2010.0048]

91 **Lee YS**, Jun HS. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. *Mediators Inflamm* 2016; **2016**: 3094642 [PMID: 27110066 DOI: 10.1155/2016/3094642]

92 **Lee YS**, Park MS, Choung JS, Kim SS, Oh HH, Choi CS, Ha SY, Kang Y, Kim Y, Jun HS. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. *Diabetologia* 2012; **55**: 2456-2468 [PMID: 22722451 DOI: 10.1007/s00125-012-2592-3]

93 **Arakawa M**, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. *Diabetes* 2010; **59**: 1030-1037 [PMID: 20068138 DOI: 10.2337/db09-1694]

94 **Bułdak Ł**, Machnik G, Bułdak RJ, Łabuzek K, Bołdys A, Belowski D, Basiak M, Okopień B. Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner. *Pharmacol Rep* 2016; **68**: 329-337 [PMID: 26922535 DOI: 10.1016/j.pharep.2015.10.008]

95 **Kodera R**, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. *Diabetologia* 2011; **54**: 965-978 [PMID: 21253697 DOI: 10.1007/s00125-010-2028-x]

96 **Kim S**, Jeong J, Jung HS, Kim B, Kim YE, Lim DS, Kim SD, Song YS. Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke. *Exp Neurobiol* 2017; **26**: 227-239 [PMID: 28912645 DOI: 10.5607/en.2017.26.4.227]

97 **Wang XC**, Gusdon AM, Liu H, Qu S. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. *World J Gastroenterol* 2014; **20**: 14821-14830 [PMID: 25356042 DOI: 10.3748/wjg.v20.i40.14821]

98 **Wang Y**, Parlevliet ET, Geerling JJ, van der Tuin SJ, Zhang H, Bieghs V, Jawad AH, Shiri-Sverdlov R, Bot I, de Jager SC, Havekes LM, Romijn JA, Willems van Dijk K, Rensen PC. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. *Br J Pharmacol* 2014; **171**: 723-734 [PMID: 24490861 DOI: 10.1111/bph.12490]

99 **Derosa G**, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, Fogari E, Maffioli P. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes. *Diabet Med* 2012; **29**: 1515-1523 [PMID: 22540883 DOI: 10.1111/j.1464-5491.2012.03699.x]

100 **Bunck MC**, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, Taskinen MR, Yki-Järvinen H, Smith U. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. *Diabetes Care* 2010; **33**: 1734-1737 [PMID: 20424219 DOI: 10.2337/dc09-2361]

101 **Daousi C**, Pinkney JH, Cleator J, Wilding JP, Ranganath LR. Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state? *Regul Pept* 2013; **183**: 54-61 [PMID: 23499806 DOI: 10.1016/j.regpep.2013.03.004]

102 **Varanasi A**, Patel P, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors. *Endocr Pract* 2012; **18**: 140-145 [PMID: 21856595 DOI: 10.4158/EP11169.OR]

103 **Dandona P**, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. *J Am Coll Cardiol* 2009; **53**: S14-S20 [PMID: 19179212 DOI: 10.1016/j.jacc.2008.10.038]

104 **Mao XM**, Liu H, Tao XJ, Yin GP, Li Q, Wang SK. Independent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetes. *Diabetes Metab Res Rev* 2009; **25**: 435-441 [PMID: 19405039 DOI: 10.1002/dmrr.968]

105 **Takebayashi K**, Aso Y, Inukai T. Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. *Metabolism* 2004; **53**: 693-699 [PMID: 15164314 DOI: 10.1016/j.metabol.2004.01.003]

106 **Jansen HJ**, Stienstra R, van Diepen JA, Hijmans A, van der Laak JA, Vervoort GM, Tack CJ. Start of insulin therapy in patients with type 2 diabetes mellitus promotes the influx of macrophages into subcutaneous adipose tissue. *Diabetologia* 2013; **56**: 2573-2581 [PMID: 24065152 DOI: 10.1007/s00125-013-3018-6]

**P-Reviewer:** Su CC **S-Editor:** Dou Y **L-Editor: E-Editor:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** Greece

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0